Citations

Clear

33 citation(s) found for "Hoffman, Eric A".

Genetic and Clinical Heterogeneity in eIF2B-Related Disorder
Maletkovic, Jelena , Gorospe, J. Rafael, Gordon, Erynn S. , Mintz, Michelle, Hoffman, Eric P. , Alper, Gülay, Singhal, Bhim , Amartino, Hernán , Brown, Candida, Chan, Alicia , Renaud, Deborah L. , Geraghty, Michael T. , Jensen, Lloyd, Şenbil, Nesrin , Kadom, Nadja , Nazarian, Javad , Feng, Yuanjian, Wang, Zuyi, Morizono, Hiroki , Vanderver, Adeline , Schiffmann, Raphael , Lynch, David R. , Harding, Cary O. , Hartka, Thomas , Nazarian, Javad

Mayo Clinic

Journal of Child Neurology | February 8, 2008 | Volume: 23 | Issue: 2 | Pages: 205-215

10.1177/0883073807308705 | PMID 18263758 Get It

Eukaryotic initiation factor 2B (eIF2B)-related disorders are heritable white matter disorders with a variable clinical phenotype (including vanishing white matter disease and ovarioleukodystrophy) and an equally heterogeneous genotype. We report 9 novel mutations in the EIF2B genes in our subject population, increasing the number of known mutations to more than 120. Using homology modeling, we have analyzed the impact of novel mutations on the 5 subunits of the eIF2B protein. Although recurrent mutations have been found at CpG dinucleotides in the EIF2B genes, the high incidence of private or low frequency mutations increases the challenge of providing rapid genetic confirmation of this disorder, and limits the application of EIF2B screening in cases of undiagnosed leukodystrophy.
Genetic Determinants of Emphysema Distribution in the National Emphysema Treatment Trial
DeMeo, Dawn L. , Hoffman, Eric A. , Litonjua, Augusto A. , Lazarus, Ross , Sparrow, David , Benditt, Joshua O., Scanlon, Paul D., Sciurba, Frank C. , Utz, James P., Reilly, John J. , Silverman, Edwin K. , Hersh, Craig P. , Criner, Gerard J. , Make, Barry J. , Martínez, Fernando J. , Hoffman, Eric A

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | March 15, 2007 | Volume: 176 | Issue: 1 | Pages: 42-48

10.1164/rccm.200612-1797oc | PMID 17363767 Get It

Abstract Rationale Computed tomography (CT) scanning of the lung may reduce phenotypic heterogeneity in defining subjects with chronic obstructive pulmonary disease (COPD), and allow identification of genetic determinants of emphysema severity and distribution. Objectives We sought to identify genes associated with CT scan distribution of emphysema in individuals without α1-antitrypsin deficiency but with severe COPD. Methods We evaluated baseline CT densitometry phenotypes in 282 individuals with emphysema enrolled in the Genetics Ancillary Study of the National Emphysema Treatment Trial, and used regression models to identify genetic variants associated with emphysema distribution. Measurements and Main Results Emphysema distribution was assessed by two methods—assessment by radiologists and by computerized density mask quantitation, using a threshold of −950 Hounsfield units. A total of 77 polymorphisms in 20 candidate genes were analyzed for association with distribution of emphysema. GSTP1, EPHX1, and MMP1 polymorphisms were associated with the densitometric, apical-predominant distribution of emphysema (p value range = 0.001–0.050). When an apical-predominant phenotype was defined by the radiologist scoring method, GSTP1 and EPHX1 single-nucleotide polymorphisms were found to be significantly associated. In a case–control analysis of COPD susceptibility limited to cases with densitometric upper-lobe–predominant cases, the EPHX1 His139Arg single-nucleotide polymorphism was associated with COPD (p = 0.005). Conclusions Apical and basal emphysematous destruction appears to be influenced by different genes. Polymorphisms in the xenobiotic enzymes, GSTP1 and EPHX1, are associated with apical-predominant emphysema. Altered detoxification of cigarette smoke metabolites may contribute to emphysema distribution, and these findings may lead to further insight into genetic determinants of emphysema.
Future Research Directions in Acute Lung Injury: Summary of a National Heart, Lung, and Blood Institute Working Group
Matthay, Michael A. , Esmon, Charles, Bhattacharya, Jahar , Floros, Joanna, Gimbrone, Michael A., Hubmayr, Rolf D., Matalon, Sadis , Munford, Robert S., Parsons, Polly E., Slutsky, Arthur S. , Tracey, Kevin J. , Ward, Peter A. , Gail, Dorothy B., Harabin, Andrea L., Zimmerman, Guy A. , Esmon, Charles T., Coller, Barry S. , Doerschuk, Claire M. , Hoffman, Eric P. , Leppert, Mark

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | March 27, 2003 | Volume: 167 | Issue: 7 | Pages: 1027-1035

10.1164/rccm.200208-966ws | PMID 12663342 Get It

Abstract Acute lung injury (ALI) and its more severe form, the acute respiratory distress syndrome (ARDS), are syndromes of acute respiratory failure that result from acute pulmonary edema and inflammation. The development of ALI/ARDS is associated with several clinical disorders including direct pulmonary injury from pneumonia and aspiration as well as indirect pulmonary injury from trauma, sepsis, and other disorders such as acute pancreatitis and drug overdose. Although mortality from ALI/ARDS has decreased in the last decade, it remains high. Despite two major advances in treatment, low VT ventilation for ALI/ARDS and activated protein C for severe sepsis (the leading cause of ALI/ARDS), additional research is needed to develop specific treatments and improve understanding of the pathogenesis of these syndromes. The NHLBI convened a working group to develop specific recommendations for future ALI/ARDS research. Improved understanding of disease heterogeneity through use of evolving biologic, genomic, and genetic approaches should provide major new insights into pathogenesis of ALI. Cellular and molecular methods combined with animal and clinical studies should lead to further progress in the detection and treatment of this complex disease.